MoonLake Immunotherapeutics Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
50MoonLake Immunotherapeutics's Business Model
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
About MoonLake Immunotherapeutics
Website: https://www.moonlaketx.com
CEO (Chief Executive Officer): Dr. Jorge Santos da Silva
IPO date: 2020-10-20
Contact
Country: CH
Address: Dorfstrasse 29
City: Zug
State: None
Phone: 41 415108022
Zip Code: 6300
Other
CIK: 0001821586
ISIN: KY61559X1045
CUSIP: 61559X104
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
